Intravenous (IV) push administration can provide clinical and practical advantages over longer IV infusions in multiple clinical scenarios, including in the emergency department, in fluid-restricted patients, and when supplies of diluents are limited. In these settings, conversion to IV push administration may provide a solution. This
Introduction
Antibiotics are commonly administered intravenous (IV) medications. Many of these drugs can be administered via IV push, intermittent IV infusion, and/or continuous IV infusion, depending on the medication. IV push allows for administration of an antibiotic in a minimal fluid volume. Small fluid volumes can be particularly useful in patients who are fluidrestricted, such as patients with acute volume overload or acute renal failure. 1 In addition, the faster administration time may provide advantages in the emergency department (ED), so that time-to-first-dose can be shortened. 2, 3 There may also be interest in IV push administration in the setting of drug or fluid shortages, such as the current shortage of small volume parenteral (SVP) solutions (ie, 50 or 100 mL bags for intermittent IV infusion). 4 In response, the American Society of Health-Systems Pharmacists recommends switching medication administration to IV push when possible to help conserve SVP supplies in the context of a shortage. Therefore, the purpose of this article is to summarize the available data that support IV push administration of antibiotics in adults.
Methods
A list of commercially available injectable antibiotics was generated from The Sanford Guide and the Food and Drug Administration (FDA) Orange Book. 5, 6 The prescribing information (PI) was used as the primary resource for FDAapproved routes of administration and stability data. The PIs for vials for reconstitution were selected if available because vial formulations are most readily prepared for IV push administration. Additional tertiary drug resources were used to confirm the information found in the PI and provide additional data, if available. [60] [61] [62] [63] [64] [65] [66] Primary literature citations from tertiary sources were reviewed in their full-text form. A primary literature search was also performed of the MEDLINE and International Pharmaceutical Abstracts (IPA) databases. Each drug name was paired with the following terms to capture published data on IV push administration: intravenous, inject*, parenteral*, "administration and dosage"[MeSH Subheading], push, bolus, rapid, fast. All sources were consulted for each drug to ascertain consensus recommendations; in cases when information could only be located in one source, a note is included in the comment column of Table 1 or in the text summaries for the antibiotics. Polypropylene syringe, 40 mg/mL 63, 71 : 30 d
at 4°C or 25°C Plastic syringe, 40 mg/mL 63, 72 : average loss of 16% after 30 d and brown precipitate formed at both 4°C and 25°C
Glass syringe, 40 mg/mL 63, 72 : average loss of 7% after 30 d, brown precipitate formed at 60 d at both 4°C and 25°C Possible instability with storage in plastic packaging due to potential oxygen exposure 63, 73 Off-label administration For assigning beyond use dates, in addition to stability data, USP <797> recommendations for sterility still apply. The shorter of the times should be used.
c Clinical Pharmacology reported 100 mg/min as maximum rate; however, this information could not be confirmed in additional resources. In addition, this rate is slower than what would be administered if following PIrecommended dilution and administration. Table 1 provides a summary of antibiotics that can be administered IV push. Stability data are limited to solutions (eg, concentrations, diluents) that can be used for IV push administration. Because there is no exact definition of IV push and a wide range of administration durations were considered IV push in the original sources, Table 1 separates administration recommendations into 2 categories. Administration over 5 minutes or less are listed as IV push, while administration over longer durations of time (eg, over 5-10 minutes) are listed as slow IV injection; however, specific administration times are provided. Figure 1 lists antibiotics that had no data or limited data suggesting IV push as a viable administration method; therefore, these antibiotics are excluded from Table 1 .
Aminoglycosides
None of the aminoglycosides are indicated for IV push administration. [7] [8] [9] 46 Aminoglycosides are generally not recommended for IV push administration due to the concern that elevated peak levels after rapid administration may cause toxicity, such as ototoxicity. 9, 65, 88 Specifically, the PI for tobramycin notes that peak serum levels may exceed 12 μg/mL when administered over periods <20 minutes. 9 However, IV push administration of gentamicin and tobramycin has been reported frequently in primary literature. [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] Table 1 includes a summary of studies with sufficient detail to replicate administration, including a descriptive report demonstrating that gentamicin and tobramycin can be safely administered IV push based on experience with 5593 doses in the setting of outpatient parenteral antibiotic therapy (OPAT). 67 In addition to the studies cited in Table 1 , gentamicin has reportedly been administered over time periods ranging from <10 seconds to 5 minutes, [89] [90] [91] [93] [94] [95] [96] while tobramycin has been administered over time periods ranging from 15 seconds to 5 minutes. 89, 90, [96] [97] [98] [99] [100] [101] Most administration times for gentamicin and tobramycin ranged from approximately 3 to 5 minutes. These studies were of varying quality and instructions for preparation were not described. There are limited reports of IV push administration with amikacin; one healthy volunteer study (n = 5) evaluated administration of 7.5 mg/kg directly from the manufacturer vial (250 mg/mL) over 2 minutes, but this resulted in potentially toxic peak serum concentrations (68-122 μg/mL). 102 Amikacin has been administered over 3 minutes and 5 minutes, respectively, in 2 additional pharmacokinetic studies; however, dilution and preparation instructions were not reported. 103, 104 Reports of streptomycin administered via IV push were not identified.
Carbapenems
Of the carbapenems, only meropenem is FDA-approved to be administered IV push. 11 Doripenem and meropenem/ vaborbactam should only be given via intermittent IV infusion; no data are available to support IV push administration. 35, 37 One pharmacokinetic study was identified describing administration of imipenem/cilastatin 500 mg over 10 minutes in 6 patients undergoing continuous ambulatory peritoneal dialysis; the volume/concentration of the administered solution was not provided. 105 However, IV push administration of imipenem/cilastatin is not recommended due to adverse events associated with rapid administration, such as nausea and vomiting.
61, 66 Administration of ertapenem 1 gram IV push over 5 minutes was bioequivalent to the 30-minute infusion for maximum serum concentration (Cmax) and area under the curve (AUC) in a study in 12 healthy volunteers, and no serious adverse events, such as vomiting or seizures, occurred (Table 1) . 76 
Cephalosporins
Cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, and cefuroxime are FDA-approved for IV push administration. 12, [14] [15] [16] [17] [18] 20 Studies comparing IV push and short-term infusion administration of cephalosporins have generally found similar rates of phlebitis and other complications. 78, 79, 106 Although not FDA-approved, cefepime and ceftriaxone may also be administered IV push. 2, 3, 78, 79, 85 Data for cefepime are limited to use as the first-dose in the ED, with limited outcome and adverse event data provided in reports. 2, 3 One additional study evaluated cefepime administered IV push, but the required volume for preparation was 50 mL, losing volume minimization advantages of IV push. 85 Ceftriaxone IV push administration has been evaluated in several settings, including in the ED, with OPAT, and in hospitalized patients, with no noted concerns. 2, 78, 79 Additional data on ceftriaxone IV push administration exist, but the majority of studies did not robustly report both preparation and administration details or focused solely on pediatric populations. [107] [108] [109] Only 3 cephalosporins lack information for IV push administration: ceftazidime/avibactam, ceftolozane/ tazobactam, and ceftaroline.
Specific adverse events related to IV push administration of cefotaxime and ceftriaxone are noted in the literature. A potentially life-threatening arrhythmia occurred in 6 patients who received rapid (<1 minute) administration of cefotaxime through a central venous catheter.
14 Rapid ceftriaxone administration (2 grams over 5 minutes) was associated with a case of palpitation, tachycardia, restlessness, shivering, and diaphoresis in an adult. 110 Ceftriaxone has also been reported to be associated with increased biliary pseudolithiasis in children given ceftriaxone over 3 to 5 minutes, and with the formation of calcium-ceftriaxone precipitate in neonates receiving concurrent calcium-containing solutions who received ceftriaxone over 2 to 4 minutes, which led to adverse cardiopulmonary events.
111,112

Glycopeptides/Lipoglycopeptides/ Lipopeptides
Daptomycin (both Cubicin and Cubicin RF) may be administered IV push in adults when reconstituted to a concentration of 50 mg/mL. 21, 22 While this practice has been reported to be safe in adults, [113] [114] [115] a case report exists documenting an IV push-related reaction to daptomycin (Cubicin) administered over 2 minutes involving redness and a warm sensation on the face, neck, and upper chest that resolved with diphenhydramine and did not recur with rechallenge of a 30-to 40-minute infusion. 116 The newer agents of these classes are not amenable to IV push administration; dalbavancin, oritavancin, and telavancin are administered via extended infusions ranging from 1 to 3 hours, and no recent literature reports their administration over shorter periods. [38] [39] [40] Vancomycin, because of the risk for infusion reaction (ie, "red-man syndrome"), should be administered no more rapidly than 10 mg/minute or over a period of ≥60 minutes, whichever is longer. 60, 61, 65, 66 Infusion reactions can be mediated by both the concentration and rate of administration of vancomycin. For patients in need of fluid restriction, vancomycin may be administered at concentrations up to 10 mg/ mL, though this may increase the risk for infusion reaction.
Fluoroquinolones
Fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) are not recommended for IV push administration due to adverse events associated with rapid administration. [57] [58] [59] 61, 66 These adverse events include venous irritation with ciprofloxacin, hypotension with levofloxacin, and an increase in the incidence and magnitude of QT prolongation with moxifloxacin. In addition, moxifloxacin is only available in premix formulations intended for intermittent IV infusion. 6, 58 In order to reduce venous irritation, slow IV infusion of ciprofloxacin into a large vein is recommended. 59 Although reports of ciprofloxacin administration over a period ranging from 3 to 15 minutes were identified, these studies did not specifically aim to evaluate the safety and efficacy of the IV push administration. [117] [118] [119] In 2 pharmacokinetic studies in healthy volunteers, ciprofloxacin was administered via rapid injection over 3 or 5 minutes, but the volume and concentration of the administered solutions were not specified. 117, 118 In one of these studies, observed adverse events with administration of ciprofloxacin 250 mg over 5 minutes in 8 healthy volunteers included localized numbness (n = 1), local thrombophlebitis (n = 1), and nausea (n = 1). 117 In another study in 12 healthy volunteers, ciprofloxacin 50 mg and 100 mg was prepared in 50 mL normal saline and administered over 15 minutes with a constant pump, with no observed adverse events. 119 However, these doses are lower than those commonly used in clinical practice.
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Penicillins and Monobactam
Among the penicillins, ampicillin may be administered IV push or as a slow IV injection after reconstitution, depending on the dose. 26 Administration faster than recommended by the PI may increase the risk of seizures. 26, 60, 65 In addition, ampicillin has limited stability, which decreases with increasing concentrations. 63 Nafcillin and oxacillin require administration via slow IV injection (eg, over 5-10 minutes). 28, 29 Phlebitis may occur if these agents are injected too rapidly. 60 Of note, profound hypotension has been reported among patients receiving IV push administration of nafcillin during coronary artery bypass graft surgery, presumed to be due to histamine-mediated vasodilation. 120 Penicillin G and piperacillin/tazobactam are not recommended for IV push administration. Ampicillin/sulbactam is recommended to be diluted in volumes that may preclude practical administration via slow IV injection (eg, 1.5 g vials in 50 mL to obtain maximum 30 mg/mL concentration). 27 Although a study in 16 patients undergoing colorectal surgery reported IV push administration of 2 g/1 g ampicillin/ sulbactam over 3 minutes, the concentration of the solution was not reported. 121 Similarly to ampicillin, seizures may occur with rapid administration of ampicillin/sulbactam. 66 Finally, the monobactam aztreonam is indicated for IV push administration after reconstitution of vials.
23
Polymyxins
Colistimethate sodium can be administered IV push. 25 After reconstitution, the manufacturer recommends use within 7 days. However, colistimethate sodium can hydrolyze to colistin in aqueous solution. Although this conversion was minimally observed in one stability study (<1% after storage of reconstituted solution at 4° or 25°C for 7 d in the dark), the authors cautioned that reconstitution should still be done as close to administration as possible, and if it is necessary to store the solution, they recommend storage at 4°C to minimize bacterial contamination. 122 With regard to the safety of IV push administration, 1 patient out of 12 in a trial assessing the safety and tolerability of IV push colistimethate reported dizziness/lack of coordination after receiving 160 mg in 10 mL over 5 minutes. 123 This resolved when the patient was switched to an intermittent IV infusion over 30 minutes. Polymyxin B is FDA-approved to be given as an IV infusion, intramuscularly, or intrathecally. 45 Administration of polymyxin B over a period <30 minutes is not recommended, and rapid IV injections should be avoided due to the potential for nephro-or neurotoxicity. 62, 124 Tetracyclines Doxycycline, minocycline, and tigecycline are recommended to be administered as an intermittent IV infusion and are not suitable for IV push administration. [42] [43] [44] The PIs for doxycycline and minocycline specifically state that rapid administration is not recommended, and oral administration is preferred over parenteral administration. 42, 43 Phlebitis and burning have been observed with more concentrated solutions of doxycycline. 65, 125 
Others
Of the antibiotics that are not included in the classes already discussed, only chloramphenicol can be administered IV push. 24 All of the other agents have specific statements against IV push administration in at least one tertiary resource. [60] [61] [62] [63] 65, 66 Of note, Seifert and colleagues documented a report of severe nausea, cramping, and hypotension after administration of erythromycin 1 g in 100 mL of normal saline over 10 minutes. 126 In addition, Aucoin and colleagues reported a case of complete heart block following administration of clindamycin 600 mg over several minutes; the same patient tolerated subsequent clindamycin infusions over 30 minutes without incident. 127 Rapid lincomycin administration has also been associated with severe cardiac events including cardiopulmonary arrest. 128 Linezolid and metronidazole are not available in a vial formulation so these drugs are not practical to administer IV push. 6, 51, 52 One observational pharmacokinetic study documented rapid IV push of metronidazole 500 mg over 5 minutes, but the volume/concentration of the administered solution was not specified so these data are not readily applicable to current clinical practice.
129
Practical Considerations for IV Push Antibiotics
Several organizations have issued guidance or recommendations for safe IV administration practices. 130 The Institute for Safe Medication Practices (ISMP) provides guidance on adult IV push medication safety. 131 Briefly, this guidance supports preparation of IV push medications in the pharmacy so that a ready-to-administer form can be provided to patient care areas. In cases where immediate administration is required for medication stability, preparation and dilution of the medication can occur in patient care areas. In those instances, dilution should take place in a clean, uncluttered area with clear instructions on the type and volume of diluent that is needed. Syringes should be promptly labeled; supplying blank, readyto-apply labels may help with adherence to that step. Considerations for safe administration of IV push medications can be found in the ISMP guidance document. The 2016 Infusion Nurses Society (INS) Infusion Therapy Standards of Practice largely mirror the ISMP recommendations for safe preparation of medications for IV push administration. 132 Osmolality is a concern when administering concentrated solutions. The 2016 INS Infusion Therapy Standards of Practice state that solutions with osmolality >900 mOsm/kg should be administered through a central line and solutions with osmolalities below this limit can be administered via peripheral or midline catheters. 132 The Standards of Practice do not have any statements that connect osmolality and administration rate; therefore, there does not seem to be any added concern with IV push administration of solutions with higher osmolalities compared with slower administration rates. Osmolality data is not readily available in product labeling or other tertiary resources and most published osmolality values are based on historical literature that is not readily applicable to current practice. 1, 78, [133] [134] [135] With the limitation that not all agents have relevant data, our review of all available published and unpublished (manufacturer-supplied) osmolality information for the antibiotics that can be administered IV push suggests that the recommended solutions for IV push administration all have osmolalities well below 900 mOsm/kg.
Additional steps that help ensure safe use of IV push medications include providing a specific administration duration on the label or in the electronic medication administration record (eg, "administer over 10 minutes" rather than "slow IV injection"). 131 Nurse education on proper dilution of IV push medications may also facilitate proper preparation. A 2014 ISMP survey found that 83% of nurse respondents further dilute certain IV push medications prior to administration. 136 Unnecessary dilution of medications can lead to contamination of sterile products, dosing errors, or administration errors. Multidose vials should not be kept in patient care areas per the Centers for Disease Control and Prevention One & Only Campaign, which prevents both inadvertent use in multiple patients and errors related to IV push administration of these solutions.
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Pharmacodynamic Considerations for IV Push Antibiotics
The pharmacodynamic effect of antibiotics can be generalized into either concentration-dependent or time-dependent bactericidal activity. 138 For agents that are concentrationdependent, maximizing the AUC per unit of time in relation to the bacterial minimum inhibitory concentration (MIC) generally increases the rapidity of bacterial killing and thus increases the likelihood of a good clinical outcome. For example, daptomycin has concentration-dependent bactericidal activity and a change in the rate of infusion (eg, a 30-minute infusion versus a 5-minute injection) does not significantly affect the resulting AUC. For beta-lactams, increasing the infusion duration can substantially increase the duration of time that the drug concentration remains above the MIC (T > MIC); therefore, changing from an infusion to IV push administration may negatively affect the pharmacodynamics of these agents. One Monte Carlo simulation study and one healthy volunteer pharmacokinetic study have investigated the impact of IV push administration. 76, 139 Based on these results, 3-to 5-minute IV push injections and 30-minute infusions of aztreonam, cefepime, ertapenem, and meropenem are expected to achieve similar T > MIC profiles.
In contrast, the difference in T > MIC between a 3-to 5-minute IV push injection (or 30-minute infusion) and an extended (eg, over 3 or 4 hours) or continuous infusion can be clinically significant. 140 Several studies have found that extended and continuous infusion strategies are associated with improved clinical cure and survival, particularly in severely ill patients, compared with shorter infusion durations. [141] [142] [143] Therefore, current data do not support the substitution of IV push administration for extended or continuous infusion schemes in patients who are critically ill, immunocompromised, or infected with organisms with MICs at or above the clinical breakpoint for susceptibility (eg, Pseudomonas with a piperacillin/tazobactam MIC of 16 μg/mL).
Conclusion
Several antibiotics, particularly in the cephalosporin class, are FDA-approved for IV push or slow IV injection administration. In addition, there are primary literature data that support IV push administration of cefepime, ceftriaxone, ertapenem, gentamicin, and tobramycin. Syringe stability data are not available for all antibiotics, which may preclude IV push administration if preparation in patient care areas for immediate use is not possible. Precautions should be taken to ensure safe IV push administration, including clear labeling and staff education. Pharmacodynamic changes due to IV push administration should be considered, including effects on time above MIC when administering antibiotics via IV push that are normally administered as extended or continuous infusions.
